FRIDAY, September 19, 2025 (News) — A study shared at the European Association for the Study of Diabetes’ annual conference in Vienna, which took place from September 15 to 19, found that hormone replacement therapy patches pose a reduced risk to the cardiovascular system compared to oral HRT in women suffering from type 2 diabetes.
Matthew Anson, affiliated with the University of Liverpool in the United Kingdom, along with his team, utilized TriNetX electronic health record data to examine cardiovascular risk and cancers related to the gynecological system and estrogen among women with type 2 diabetes who were using or not using HRT during midlife. The study analyzed information from 24,986 participants.
The study revealed that women with diabetes who used transdermal HRT had a higher risk of deep vein thrombosis (hazard ratio [HR], 1.90; P = 0.002), ischemic heart disease (HR, 1.77; P < 0.001), and cerebral infarction (HR, 1.89; P < 0.001) compared to those using HRT without diabetes. No differences were observed in the rates of pulmonary embolism or cancers of the breast, ovary, or endometrium. For individuals with diabetes, transdermal HRT was linked to a lower risk of ischemic heart disease (HR, 0.75; P < 0.001) than nonuse. In this group, oral HRT was associated with a greater risk of ischemic heart disease (HR, 1.21; P = 0.004) and pulmonary embolism (HR, 2.01; P < 0.001), but no significant differences were found for other outcomes.
According to our research, administering up to five years of transdermal HRT that has been approved by regulators seems safe for a significant group of middle-aged women with type 2 diabetes,” Anson stated. “Nevertheless, due to higher risks associated with oral HRT, we recommend that women with type 2 diabetes should avoid being given oral estrogen treatment.
jasdooit 
Leave a comment